Clinical Trial Update: Safety and Tolerability of SPD485 in Children Aged 6-12 Diagnosed With ADHD and Previously Participated in MTS Trials [Phase 3]

View source ↗

Summary

Phase 3 trial update reports safety and tolerability data for SPD485 in children ages 6-12 with ADHD who previously participated in MTS trials.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• SPD485

Snippet

Sponsor: Noven Therapeutics | Conditions: Attention Deficit Disorder With Hyperactivity | Phase 3 | Status: COMPLETED